NAVICAN PRECISION CANCER CARE - Trademark Details
Status: 700 - Registered
Serial Number
87978077
Registration Number
5771247
Word Mark
NAVICAN PRECISION CANCER CARE
Status
700 - Registered
Status Date
2019-06-04
Filing Date
2017-05-30
Registration Number
5771247
Registration Date
2019-06-04
Mark Drawing
4000 - Standard character mark
Typeset
Published for Opposition Date
2017-11-07
Attorney Name
Law Office Assigned Location Code
M80
Employee Name
LEASER, ANDREW C
Statements
Disclaimer with Predetermined Text
"PRECISION CANCER CARE"
Goods and Services
Pharmaceutical benefit management services; insurance claims processing in the field of diagnostics and pharmaceutical claims; providing a database featuring information and statistics about patient reimbursement and insurance coverage for diagnostics and pharmaceuticals; reimbursement payment processing in the field of diagnostics and pharmaceutical claims; providing information in the field of financial support options and resources for prescribers, patients and the pharmaceutical industry; providing patient reimbursement and insurance coverage information in the field of drug reimbursement for prescribers, patients and the pharmaceutical industry; providing patient reimbursement and insurance coverage information in the field of diagnostics reimbursement for providers and patients; and financial administration of diagnostics and pharmacy reimbursement programs and services
Goods and Services
Medical, clinical and scientific research in the field of oncology, namely, research relating to genetic diagnostic assays and pharmaceuticals for personalized diagnosis, treatment and prevention of cancer; scientific and technological services, namely, research services for medical purposes in the field of genetic diagnostic assays and pharmaceuticals research for personalized diagnosis, treatment and prevention of cancer; providing medical and scientific research information and scientific consulting in the field of genetic diagnostic assays and pharmaceuticals for diagnosis, treatment and prevention of cancer; conducting early evaluations in the field of new genetic diagnostics assays and pharmaceuticals; development, evaluation and medical and scientific research of genetic diagnostic assays for personalized diagnosis, treatment and prevention of cancer; laboratory research services relating to genetic diagnostic assays for personalized diagnosis, treatment and prevention of cancer; providing medical and scientific research information in the field of genetic diagnostic assays, pharmaceuticals, clinical trials and genetics; technical consulting related to scientific and medical studies in the field of genetic diagnostic assay and pharmaceuticals for personalized diagnosis, treatment and prevention of cancer; basic and clinical research in the field of oncology, namely, researching genetic diagnostic assays and pharmaceuticals for personalized diagnosis, treatment and prevention of cancer; providing medical and scientific research information in the field of genetic diagnostic assays, pharmaceuticals and clinical trials for personalized diagnosis, treatment and prevention of cancer; custom design and development of chemical reagants and multiplex sequencing assays for personalized diagnosis, treatment and prevention of cancer; providing an on-line computer database featuring medical and scientific research information in the field of oncology that allows for input and collection of scientific and research data and information relating to genetic diagnostic assays and pharmaceuticals for diagnosis, treatment and prevention of cancer; data collection for research purposes, namely, data mining and pattern recognition, designing clinical studies, and generating genomic data from patient samples for personalized diagnosis, treatment and prevention of cancer; data collection for research purposes, namely, the collection and systematic sorting of clinical and patient data comprising patient specific clinical data and scientific clinical studies relating to genetic diagnostic assays and pharmaceuticals for personalized diagnosis, treatment and prevention of cancer; data collection for research purposes, namely, the collection of mathematical and statistical data, clinical data, patient data and data of clinical studies relating to clinical response to cancer treatments for personalized diagnosis, treatment and prevention of cancer; compiling data for research purposes in the field of medical science, namely, compiling patient specific molecular and genomic data, patient specific clinical data and scientific clinical studies for personalized diagnosis, treatment and prevention of cancer; providing a website featuring technology with a web-based interface where medical professionals can view genetic test results and interpretations of the results by scientists and medical professionals in the field of genomics, and select the appropriate treatment and order the necessary pharmaceutical products
Classification Information
International Class
042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software; legal services. - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software; legal services.
US Class Codes
100, 101
Class Status Code
6 - Active
Class Status Date
2017-06-06
Primary Code
042
First Use Anywhere Date
2018-04-23
First Use In Commerce Date
2018-04-23
Current Trademark Owners
Party Name
Party Type
31 - 1st New Owner Entered After Registration
Legal Entity Type
54
Address
Please log in with your Justia account to see this address.
Trademark Owner History
Party Name
Party Type
31 - 1st New Owner Entered After Registration
Legal Entity Type
54
Address
Please log in with your Justia account to see this address.
Party Name
Party Type
30 - Original Registrant
Legal Entity Type
03 - Corporation
Address
Please log in with your Justia account to see this address.
Party Name
Party Type
20 - Owner at Publication
Legal Entity Type
03 - Corporation
Address
Please log in with your Justia account to see this address.
Party Name
Party Type
10 - Original Applicant
Legal Entity Type
03 - Corporation
Address
Please log in with your Justia account to see this address.
Correspondences
Name
JOSHUA G. GIGGER
Address
Please log in with your Justia account to see this address.
Prior Registrations
Relationship Type | Reel Number |
Continuity Parent | 87468478 |
Madrid International Filings
Entry Number
1
Reference Number
A0071255
Original Filing Date USPTO
2017-11-07
International Registration Number
1389030
International Registration Date
2017-11-07
International Status Code
480
International Renewal Date
2027-11-07
Madrid History Events | ||
Date | Code | Description |
2019-10-17 | CHGOW | CHANGE OF OWNER RECEIVED FROM IB |
2019-10-17 | CHGOW | CHANGE OF OWNER RECEIVED FROM IB |
2017-11-07 | NEWAP | NEW APPLICATION FOR IR RECEIVED |
2017-11-08 | MCERT | MANUALLY CERTIFIED |
2017-11-08 | APPST | IR CERTIFIED AND SENT TO IB |
2017-12-05 | IRREG | IRREGULARITY NOTICE RECEIVED FROM IB |
2018-01-02 | IRRCV | IRREGULARITY RESPONSE RECEIVED FROM APPLICANT |
2018-01-12 | IRRAC | RESPONSE TO IRREGULARITY REVIEWED AND ACCEPTED |
2018-01-12 | IRSNT | IRREGULARITY RESPONSE SENT TO IB |
2018-02-15 | CREAT | APPLICATION FOR IR REGISTERED BY IB |
2019-08-07 | CBMPP | CEASING OF EFFECT PROCESSED |
2018-04-23 | CBPCP | PARTIAL CEASING OF EFFECT TO BE PROCESSED |
2019-08-07 | CBPSP | PARTIAL CEASING OF EFFECT NOTICE SENT TO IB |
2018-04-26 | CBNAR | CEASING OF EFFECT REVIEWED - NO ACTION REQUIRED BY OFFICE |
2018-08-24 | PDBNX | DIVISION OF BASE APPLICATION PROCESSED BY IB |
2019-08-05 | CBPCP | PARTIAL CEASING OF EFFECT TO BE PROCESSED |
2019-09-18 | CBNAR | CEASING OF EFFECT REVIEWED - NO ACTION REQUIRED BY OFFICE |
2018-07-16 | DBCSP | DIVISIONAL OF BASE APP NOTICE SENT TO IB |
2018-07-14 | DBCRP | DIVISIONAL OF BASE APP NOTICE CREATED, TO BE SENT TO IB |
2019-09-04 | CBPCP | PARTIAL CEASING OF EFFECT TO BE PROCESSED |
2019-10-04 | PCBNP | PARTIAL CEASING OF EFFECT PROCESSED BY IB |
Trademark Events
Event Date | Event Description |
2017-06-02 | NEW APPLICATION ENTERED IN TRAM |
2017-06-06 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM |
2017-08-17 | ASSIGNED TO EXAMINER |
2017-08-24 | EXAMINERS AMENDMENT -WRITTEN |
2017-08-24 | EXAMINERS AMENDMENT E-MAILED |
2017-08-24 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
2017-08-24 | EXAMINER'S AMENDMENT ENTERED |
2017-08-26 | EXAMINERS AMENDMENT -WRITTEN |
2017-08-26 | EXAMINERS AMENDMENT E-MAILED |
2017-08-26 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
2017-08-26 | EXAMINER'S AMENDMENT ENTERED |
2017-09-16 | APPROVED FOR PUB - PRINCIPAL REGISTER |
2017-10-01 | ASSIGNED TO LIE |
2017-10-18 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
2017-11-07 | PUBLISHED FOR OPPOSITION |
2017-11-07 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
2018-01-02 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
2018-06-29 | TEAS STATEMENT OF USE RECEIVED |
2018-06-29 | TEAS REQUEST TO DIVIDE RECEIVED |
2018-07-13 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
2018-06-29 | DIVISIONAL REQUEST RECEIVED |
2018-07-13 | DIVISIONAL PROCESSING COMPLETE |
2018-06-29 | USE AMENDMENT FILED |
2018-07-13 | STATEMENT OF USE PROCESSING COMPLETE |
2018-08-02 | SU - NON-FINAL ACTION - WRITTEN |
2018-08-02 | NON-FINAL ACTION E-MAILED |
2018-08-02 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
2018-09-13 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
2018-09-13 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
2018-09-14 | TEAS/EMAIL CORRESPONDENCE ENTERED |
2018-10-04 | SU - FINAL REFUSAL - WRITTEN |
2018-10-04 | FINAL REFUSAL E-MAILED |
2018-10-04 | NOTIFICATION OF FINAL REFUSAL EMAILED |
2019-05-02 | SU-EXAMINER'S AMENDMENT WRITTEN |
2019-05-02 | EXAMINERS AMENDMENT E-MAILED |
2019-05-02 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
2019-05-02 | EXAMINER'S AMENDMENT ENTERED |
2019-05-02 | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED |
2019-05-03 | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED |
2019-06-04 | REGISTERED-PRINCIPAL REGISTER |
2019-08-14 | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP |